<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this issue of Science Translational Medicine, a report by Loeys et al. on mutations in the fibrillin-1 gene in patients with <z:mp ids='MP_0009932'>skin fibrosis</z:mp> (stiff skin) adds a new piece of information on a <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> that resembles systemic <z:mp ids='MP_0000612'>sclerosis</z:mp>, an <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> characterized by <z:mp ids='MP_0009932'>skin fibrosis</z:mp> and visceral organ involvement </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we discuss the implications of these findings, as well as new opportunities for targeted therapy for <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
</text></document>